Get the Stockscreener App
21.00
3.14%
-0.68
After Hours:
20.98
-0.02
-0.10%
Neurogene Inc stock is traded at $21.00, with a volume of 182.56K.
It is down -3.14% in the last 24 hours and up +29.95% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$21.68
Open:
$22
24h Volume:
182.56K
Relative Volume:
0.89
Market Cap:
$299.50M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.28%
1M Performance:
+29.95%
6M Performance:
+35.40%
1Y Performance:
-49.21%
1-Day Range:
$20.72
$22.38
1-Week Range:
$20.72
$23.53
52-Week Range:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
21.00 | 309.20M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Can trapped investors hope for a rebound in Neurogene Inc.Daily Breakout List with Smart Filters - Newser
Ranking Neurogene Inc. among high performing stocks via toolsCapital Growth Plan for New Investors - Newser
Screener Results Flag Neurogene Inc. as OversoldWatchlist for Smart Swing Trading Updated - metal.it
Why Neurogene Inc. stock attracts strong analyst attentionFree ROI Boosting Trade Opportunity Calendar - Newser
What risks could impact Neurogene Inc. stock performanceSmart Trade Mapping with Entry Details - Newser
How Neurogene Inc. stock performs during market volatilityFree Access to Smart Investment Tips - Newser
Will Neurogene Inc. Hold Gains Into CloseHigh Accuracy Alerts for ROI Traders Detected - metal.it
How does Neurogene Inc. generate profit in a changing economyWealth Building Insights With Low Risk - jammulinksnews.com
How does Neurogene Inc. compare to its industry peersInvest smarter with actionable trading signals - jammulinksnews.com
Published on: 2025-07-28 07:19:32 - Newser
What makes Neurogene Inc. stock price move sharplyWeekly Trend Watch with Market Signals - Newser
Does Neurogene Inc. stock perform well during market downturnsUnlock exclusive stock market insights - jammulinksnews.com
Is it the right time to buy Neurogene Inc. stockFind market-beating stocks for your portfolio - jammulinksnews.com
What are the latest earnings results for Neurogene Inc.Invest smarter with data-backed insights - jammulinksnews.com
What markets is DRTSW expanding into Is Neurogene Inc. stock a good long term investment option - jammulinksnews.com
Is Neurogene Inc. a good long term investmentStrong return on investment - PrintWeekIndia
What drives Neurogene Inc. stock priceTremendous growth opportunities - PrintWeekIndia
Neurogene Inc. Stock Analysis and ForecastExplosive capital gains - PrintWeekIndia
Rett bet set includes Neurogene, Taysha gene therapies - BioWorld MedTech
What analysts say about Neurogene Inc. stockFree Market Dynamics Reports - jammulinksnews.com
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
10.28%
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):